High amounts of circulating interleukin (IL)‐6 in the form of monomeric immune complexes during anti‐IL‐6 therapy. Towards a new methodology for measuring …

ZY Lu, J Brochier, J Wijdenes, H Brailly… - European journal of …, 1992 - Wiley Online Library
ZY Lu, J Brochier, J Wijdenes, H Brailly, R Bataille, B Klein
European journal of immunology, 1992Wiley Online Library
A patient with plasma cell leukemia was treated with anti‐interleukin (IL)‐6 monoclonal
antibodies (mAb) for 2 months. Using chromatography on protein A‐Sepharose, anti‐murine‐
IgG‐Sepharose, anti‐IL‐6‐mAb‐Sepharose and gel filtration at pH 2.3, we have
demonstrated that the anti‐IL‐6 mAb, by preventing the binding of IL‐6 to its cell membrane
receptor and its renal elimination, has induced huge amounts of IL‐6 to circulate in the form
of monomeric immune complexes. By using this observation, we have developed a …
Abstract
A patient with plasma cell leukemia was treated with anti‐interleukin (IL)‐6 monoclonal antibodies (mAb) for 2 months. Using chromatography on protein A‐Sepharose, anti‐murine‐IgG‐Sepharose, anti‐IL‐6‐mAb‐Sepharose and gel filtration at pH 2.3, we have demonstrated that the anti‐IL‐6 mAb, by preventing the binding of IL‐6 to its cell membrane receptor and its renal elimination, has induced huge amounts of IL‐6 to circulate in the form of monomeric immune complexes. By using this observation, we have developed a mathematical modelling that allows the determination of the overall daily production of IL‐6 in this patient, which was in the range of 15 μg per day. Overall in vivo production of cytokines has never been evaluated in animals or in humans before.
Wiley Online Library